New Research Highlights Value of Protein Test in Mesothelioma Prognosis, According to Surviving Mesothelioma

Share Article

Scientists in Italy say an immune regulator called CTLA-4 may be used to help predict mesothelioma survival.

Protein May Be Mesothelioma Prognostic Tool

CTLA-4 and Mesothelioma Prognosis

A homogeneous favorable prognostic effect was found for CTLA-4 overexpression in tissue, serum and pleural effusion.

Doctors in Italy say mesothelioma patients with the highest levels of a protein that governs immune response may live longer than patients with lower levels. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.

Researchers at cancer centers in Genoa and La Spezia, Italy tested the blood serum, tumors, and lung fluid of 45 mesothelioma patients for CTLA-4, a protein that downregulates the immune system and helps mesothelioma cells “hide” from it.

“A homogeneous favorable prognostic effect was found for CTLA-4 overexpression in tissue, serum and pleural effusion,” reports lead study author Dr. Silvio Roncella of ASL5 in La Spezia.

The new study., which was published in Cancer Immunology, Immunotherapy, found that 56 percent of the mesothelioma tissues tested expressed CTLA-4 at various levels.

“Prognostic tests are valuable not only as a way to predict mesothelioma survival, but also as tools for mesothelioma treatment planning,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “We are committed to keeping our readers informed when a biomarker like CTLA-4 shows promise as a prognostic tool.”

Read more about the potential of CTLA-4 in mesothelioma prognostic testing in the article Protein May Be Key to Mesothelioma Prognosis, now available on the Surviving Mesothelioma website.

Roncella, Silvio, et al, “CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor”, May 20, 2016, Cancer Immunology, Immunotherapy, Epub ahead of print, http://link.springer.com/article/10.1007%2Fs00262-016-1844-3

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website